CompletedNot Applicable

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

United States14 participantsStarted 2005-09

Plain-language summary

The purpose of this study is to determine whether the level of FOXA2 expression in fat tissue is a biomarker of insulin resistance. To test this hypothesis, we will perform euglycemic-hyperinsulinemic clamps in normal and obese human subjects to calculate insulin sensitivity, and see if insulin sensitivity correlates with the FOXA2 expression in subcutaneous fat.

Who can participate

Age range21 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy individuals
✓. Age 21-45 years old
✓. BMI: either \< 25, or 30-35, or \> 40
✓. All patients must be willing and able to sign an informed consent form -

Exclusion criteria

✕. Chronic illnesses other the than mild forms of illnesses related to obesity, such as hypertension, hyperlipidemia, and others, that do not require medical treatment
✕. Diabetes mellitus previously diagnosed as per subject report or an abnormal 2 hour OGTT at screening
✕. Chronic drug treatment for any medical condition
✕. Active weight reduction of more than 7 pounds in the last 3 months
✕. History of bleeding or blood clotting disorders
✕. Subjects with hemoglobin \<8.5 gm/dl
✕. Changes in smoking habits for the last 6 months
✕. Current pregnancy or current breast-feeding in women

Trial details

NCT IDNCT00229268

SponsorRockefeller University

Sponsor typeOTHER

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Insulin Resistance trials